Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat

Journal of Physiology and Pharmacology

Volumn 62, Issue 4, 2011, Pages 395-402

  Bojanowska, E ^a   Radziszewska, E ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Body weight; Cannabinoid; CB1 receptor antagonist; Exendin (9 39); Exendin 4; Food intake; Glucagon like peptide 1

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; ENERGY BALANCE; FOOD INTAKE; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; RAT; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; APPETITE DEPRESSANTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EATING; ENERGY METABOLISM; MALE; PEPTIDES; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, GLUCAGON; VENOMS;

EID: 82155181584     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Berthoud HR. Homeostatic and non-homeostatic pathways involved in the control of food intake and energy balance. Obesity 2006; 14(Suppl. 5): 1979-2008.
2. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008; 18: 158-168.
3. Mendieta-Zeron H, Lopez M, Dieguez C. Gastrointestinal peptides controlling body weight homeostasis. Gen Comp Endocrinol 2008; 155: 481-495.
4. Stengel A, Goebel M, Wang L, et al. Selective central activation of somatostatin receptor 2 increases food intake, grooming behavior and rectal temperature in rats. J Physiol Pharmacol 2010; 61: 399-407.
5. Furnes MW, Zhao CM, Stenstrom B, et al. Feeding behavior and body weight development: lessons from rats subjected to gastric bypass surgery or high-fat diet. J Physiol Pharmacol 2009; 60(Suppl. 7): 25-31.
6. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557.
7. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617.
8. Dodd GT, Stark JA, McKie S, Williams SR, Luckman SM. Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat. Neuroscience 2009; 163: 1192-1209.
9. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 323-326.
10. Huang H, Acuna-Goycolea C, Li Y, Cheng HM, Obrietan K, van den Pol AN. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: Implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci 2007; 27: 4870-4881.
11. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004; 143: 520-523.
12. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005; 49: 646-652.
13. Duncan M, Davison JR, Sharkey KA. Endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005; 22: 667-683.
14. Chambers AP, Sharkey KA, Koopmans HS. Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 2004; 82: 863-869.
15. Van Gaal LF, Risanen AM, Sheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
16. Ward SJ, Lefever TW, Rawls SM, Whiteside GT, Walker EA. Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacology 2009; 206: 155-165.
17. Garber AJ. Incretin-based therapies in the management of type 2 diabetes mellitus: rationale and reality in a managed care setting. Am J Manag Care 2010; 16(Suppl. 7): S187-S194.
18. Rodriquez de Fonseca F, Navarro M, Alvarez E, et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000; 49: 709-717.
19. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
20. Mack CM, Moore CX, Jodka CM, et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes 2006; 30: 1332-1340.
21. Bojanowska E, Nowak A. Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol 2007; 58: 349-360.
22. Barber TM, Begbie H, Levy J. The incretin pathway as a new therapeutic target for obesity. Maturitas 2010; 67: 197-202.
23. Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009; 23: 133-144.
24. Bermudez-Silva FJ, Viveros MP, McPartland JM, de Fonseca FR. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 2010; 95: 375-382.
25. Hayes MR, De Jonghe BC, Kanoski SE. Role of glucagonlike-peptide-1 receptor in the control of energy balance. Physiol Behav 2010; 100: 503-510.
26. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
27. Washington MC, Raboin SJ, Thompson W, Larsen CJ, Sayegh AI. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res 2010; 1344: 124-133.
28. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006; 55: 3387-3393.
29. 3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146: 3748-3756.
30. Bello NT, Kemm MH, Ofeldt EM, Moran TH. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol 2010; 299: R945-R952.
31. Tallett AJ, Blundell JE, Rodgers RJ. Effects of acute lowdose combined treatment with naloxone and AM 251 on food intake, feeding behavior and weight gain in rats. Pharmacol Biochem Behav 2009; 91: 358-366.
32. Rowland NF, Mukherjec M, Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 2001; 159: 111-116.
33. Orio L, Crespo I, Lopez-Moreno JA, Reyes-Cabello C, Rodriguez de Fonseca F, Gomez de Heras R. Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. Pharmacol Biochem Behav 2011; 98: 220-226.
34. Tallett AJ, Blundell JE, Rodgers RJ. Effects of acute lowdose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. Pharmacol Biochem Behav 2010; 97: 92-100.
35. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am J Physiol 2010; 299: G63-G69.
36. Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagon-like peptide-1, but not glucosedependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36-43.
37. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signaling. J Mol Endocrinol 2010; 44: 87-97.
38. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P. Hypersensitization of the orexin 1 receptor. J Biol Chem 2003; 278: 23731-23737.
39. Perez-Tilve D, Gonzalez-Matias L, Alvarez-Crespo M, et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007; 56: 143-151.
40. Green BD, Irwin N, Gault VA, Bailey CJ, O'Harte FP, Flatt PR. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J Endocrinol 2005; 185: 307-317.